Compounds > 2-diphenylmethylpiperidine
Page last updated: 2024-12-08

2-diphenylmethylpiperidine

Description

2-diphenylmethylpiperidine: structure given in first source; RN given refers to compound with no isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID160506
SCHEMBL ID729266
MeSH IDM0225504

Synonyms (31)

Synonym
2-diphenylmethylpiperidine
OPREA1_652788
AKOS001476367
STK893433
2-(diphenylmethyl)piperidine
2-benzhydrylpiperidine
2-(diphenylmethyl)piperidine; 2-benzhydrylpiperidine
A19451
A828867
519-74-4
49unk1bv8t ,
desoxypipradrol
2-dpmp
unii-49unk1bv8t
deoxypipradol
hsdb 8015
einecs 208-276-6
AM20080665
piperidine, 2-(diphenylmethyl)-
BBL020743
SCHEMBL729266
(+/-)-desoxypipradrol
2-diphenylmethylpiperidine [hsdb]
desoxypipradol
RWTNXJXZVGHMGI-UHFFFAOYSA-N
J-509279
DTXSID90897502
Q414480
LE-0263
desoxypipradrol (1mg/ml in methanol)
PD048829
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.31 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (28.57%)6.00%
Case Studies1 (14.29%)4.05%
Observational0 (0.00%)0.25%
Other4 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cyproheptadine
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.. cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.		2.420piperidines;
tertiary amine		anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist
diphenylprolinol
diphenylprolinol: a psychoactive drug; structure in first source		4.0920
piperidines
Piperidines: A family of hexahydropyridines.		5.0570
ConditionIndicatedRelationship StrengthStudiesTrials
Serotonin Syndrome
An adverse drug interaction characterized by altered mental status, autonomic dysfunction, and neuromuscular abnormalities. It is most frequently caused by use of both serotonin reuptake inhibitors and monoamine oxidase inhibitors, leading to excess serotonin availability in the CNS at the serotonin 1A receptor.		02.1310
Rhabdomyolysis
Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.		02.1310
Chemical Dependence
[description not available]		02.0810
Substance-Related Disorders
Disorders related to substance use or abuse.		02.0810
Adenoma, beta-Cell
[description not available]		01.9810
Cancer of Pancreas
[description not available]		01.9810
Insulinoma
A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.		01.9810
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		01.9810
chemdatabank.com